Apparently from the uproarious response of an angry public, Martin Shkreli, the CEO of Turing Pharmaceuticals who jacked up the price of the life saving drug Daraprim that treats parasitic infections, will now drop the price, although he hasn’t said how much.
With the New York Times and even Democratic presidential candidate Hillary Clinton publicly shaming him, the nation saw pharmaceutical companies’ stock prices to take a dive as a result. It looks like the outrage on social media was too much for Shkreli to handle.
Shkreli refused to cut the price back from $750 a pill to its original $13, promising all week he would not budge. But just a little while ago, he announced that he had a change of heart.
“Yes it is absolutely a reaction — there were mistakes made with respect to helping people understand why we took this action,” Shkreli told CNBC. “I think that it makes sense to lower the price in response to the anger that was felt by people,” Shkreli said, 32.
A satisfied Hillary Clinton voiced her agreement with the decision.
Good. https://t.co/UkOr0vfeHX
— Hillary Clinton (@HillaryClinton) September 22, 2015
After proudly battling the Twitter public since the story broke, Shkreli seems to have toned it down a little.
Watch CNBC’s report in the video below:
Leave a Reply